Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of February 28, 2026, Celldex Therapeutics, Inc. (CLDX) has a Wall Street consensus price target of $24.00, based on estimates from 19 covering analysts. With the stock currently trading at $30.09, this represents a potential downside of -20.2%. The company has a market capitalization of $2.00B.
Analyst price targets range from a low of $24.00 to a high of $24.00, representing a 0% spread in expectations. The median target of $24.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CLDX trades at a trailing P/E of -7.7x. Analysts expect EPS to grow -24.1% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how CLDX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonCLDX's consensus price target is $24, -20.2% below the current price of $30.09. The 19 analysts tracking CLDX see downside risk at present valuations.
CLDX has a consensus rating of "Buy" based on 19 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $24 implies -20.2% downside from current levels.
CLDX's current price is $30.09 with a consensus target of $24 (-20.2% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $24 for CLDX, while the most conservative target is $24. The consensus of $24 represents the median expectation. These targets typically reflect 12-month expectations.
CLDX is well covered by analysts, with 19 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CLDX stock forecast based on 19 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $24 (bear case) to $24 (bull case). The median consensus rating is "Buy".
Analysts are cautious on CLDX, with 1 Sell ratings and a price target of $24 (-20.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CLDX analyst price targets range from $24 to $24, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground.